Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Pfizer Japan to Curb Shipments and Recall Amoxapine over Carcinogen Risks
Pfizer is restricting the shipments of and eventually plans to recall its antidepressant Amoxan (amoxapine) in Japan after detecting cancer-causing impurities. The company is asking healthcare providers to stop its use in new patients and have those already on the…
To read the full story
Related Article
- Pfizer Japan to Discontinue Amoxapine after Carcinogen Issue
February 20, 2025
- Pfizer Japan Begins Amoxapine Recall, Ceases Shipments over Carcinogen Risks
February 27, 2023
- Pfizer Assesses Cancer Risk from Amoxan as “Acceptable” at “1 in 200,000 People”
October 26, 2022
- Pfizer Japan to Stop Amoxapine Shipments, Start Recall in February after Carcinogen Detection
September 7, 2022
- Nitrosamine Impurity Detected in Sitagliptin, Shipments in Japan to Continue with FDA-Set Limit: MSD/Ono
September 2, 2022
- MHLW Orders Large-Scale Carcinogen Risk Inspections, Covering Almost All Drugs
October 11, 2021
- Pfizer Japan Recalling Some Champix Products after Detecting Carcinogen
July 29, 2021
BUSINESS
- Novo Targets Double-Digit Growth in Japan in 2026, Obesity Access Key
February 12, 2026
- Takeda’s Narcolepsy Drug Accepted for US FDA Review
February 12, 2026
- FDA Rejects Regenxbio/Nippon Shinyaku’s MPS II Gene Therapy
February 12, 2026
- Celltrion to Launch Japan’s First Actemra Biosimilar in Late April
February 12, 2026
- MFN Policy Could Affect Business Outside US: Kyowa Kirin CEO
February 12, 2026
Japan’s health and finance ministers agreed late last year to go ahead with an “off-year” drug price revision in FY2027,…
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…